In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Shaping The Medical Industry, May 2016

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.

You may also be interested in...

US FDA’s ODAC Pushes Back Against ‘Leading’ Questions

The questions posed by the FDA to its Oncologic Drugs Advisory Committee for its most recent meeting all but answer themselves. The committee ultimately supported the agency’s negative view of the applications under review, but pushback during the meeting may encourage the agency to strike a more neutral tone in the future.

Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC

Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.

CIR Expert Panel’s September Safety Findings, Final 2023 Priorities

Cosmetic Ingredient Review’s panel of independent experts will be highly focused on botanical ingredients in 2023 – a sign of the times, it says. At its September meeting, the panel finalized six ingredient safety reports, advanced four tentative reports, and issued an insufficient data announcement for Phenyl-Substituted Methicones.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts